Impact of HPV on IVF and ICSI outcomes
Impact of Human Papillomavirus Carriage on IVF/ICSI Results at Brest University Hospital
University Hospital, Brest · NCT06550531
This study is testing how human papillomavirus (HPV) affects the success of fertility treatments like IVF and ICSI in women trying to get pregnant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 618 (estimated) |
| Ages | 25 Years to 38 Years |
| Sex | Female |
| Sponsor | University Hospital, Brest (other) |
| Locations | 1 site (Brest) |
| Trial ID | NCT06550531 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the effect of human papillomavirus (HPV) on fertility outcomes in women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). Conducted at the Brest University Hospital, the study will enroll new patients over a three-year period, updating HPV tests as necessary. Researchers will analyze the results of fertility treatments and pregnancy outcomes based on the HPV status of participants, aiming to clarify the virus's role in female infertility.
Who should consider this trial
Good fit: Ideal candidates are women aged 25 to 37 years with a specific level of ovarian reserve (AMH ≥ 1.1 ng/ml) seeking IVF or ICSI treatment.
Not a fit: Patients under 25 years, over 37 years, or with low ovarian reserve (AMH < 1.1 ng/ml) will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the relationship between HPV and female infertility, potentially supporting vaccination efforts.
How similar studies have performed: While the impact of HPV on male fertility has been studied, this specific investigation into its effects on female fertility is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * all etiology of infertility AMH \> ou = à 1.1 ng/ml First ou second protocol of IVF between 25 years and 37 years and 11 months Exclusion Criteria: Age \< 25 y Age \> ou = 38 y AMH \< 1.1 ng/ml patient under juridic protection rejection of participation
Where this trial is running
Brest
- CHRU de Brest — Brest, France (RECRUITING)
Study contacts
- Study coordinator: Sarah BOUEE
- Email: sarah.bouee@chu-brest.fr
- Phone: 02 98 22 39 70
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Human Papilloma Virus, Infertility, Female